CDKN2A and sarcoma: These clinical reports are in line with the observation that in MD mice, sarcomas share nonrandom genomic alterations including frequent loss of TS (such as Cdkn2a or Nf1), amplifications of oncogenes (Met, Jun), recurrent duplications of whole chromosomes 8 and 15, and DNA damage (Schmidt et al, 2011).